Loading...

Our Team

Alvin has served as CEO of Enzyvant since November 2016.  Prior to joining Enzyvant, Alvin was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin.  Prior to joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company.  Alvin has an MD from the University of Alabama, an MBA from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital.  As a native of Alabama, Alvin is a diehard fan of country music and Alabama football.
Alex is a pediatrician by training, with years of clinical experience in pediatric rheumatology, immunology, and rare diseases including lysosomal storage diseases in particular. He has longstanding relationships with international physician colleagues and patient organizations in these fields. Alex most recently served as the global medical lead for Plexcera Therapeutics, helping build the Farber disease program as well as guiding a second program aimed at treatment of bone and joint disease in mucopolysaccharidosis through a Phase I trial. Alex has lived in the US, Hungary and Germany, and is currently based out of Basel, Switzerland. Before studying medicine, Alex finished a degree in the cultural anthropology of religion and cared for an orchard of 40 fruit trees.
Dustin has been with Enzyvant since its inception in June 2016, and manages the clinical studies, external collaborations, and patient affairs. Prior to Enzyvant, Dustin worked in the business development department at Roivant Sciences, Inc., sourcing and evaluating new assets in the rare disease space. Dustin completed his medical education at Columbia University College of Physicians and Surgeons, and has a successful history as a senior consultant in the medical education industry. Dustin is an avid skier, and as a self-labeled “foodie” he claims to know a lot about the local restaurant scene.
Contact Us